| Title : Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease - Frolich_2019_Alzheimers.Res.Ther_11_18 |
| Author(s) : Frolich L , Wunderlich G , Thamer C , Roehrle M , Garcia M, Jr. , Dubois B |
| Ref : Alzheimers Res Ther , 11 :18 , 2019 |
| Abstract : Frolich_2019_Alzheimers.Res.Ther_11_18 |
| ESTHER : Frolich_2019_Alzheimers.Res.Ther_11_18 |
| PubMedSearch : Frolich_2019_Alzheimers.Res.Ther_11_18 |
| PubMedID: 30755255 |
Frolich L, Wunderlich G, Thamer C, Roehrle M, Garcia M, Jr., Dubois B (2019)
Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease
Alzheimers Res Ther
11 :18
Frolich L, Wunderlich G, Thamer C, Roehrle M, Garcia M, Jr., Dubois B (2019)
Alzheimers Res Ther
11 :18